Age, Race Affect Treatment Decision Regret in Prostate Cancer

Share this content:
Age, race, and other factors may influence treatment decisional regret among men with prostate cancer.
Age, race, and other factors may influence treatment decisional regret among men with prostate cancer.

Age, race, and other factors may influence treatment decisional regret among men with prostate cancer, according to research published online in Cancer.

Bonny B. Morris, M.S.P.H., B.S.N., R.N., of the University of North Carolina at Chapel Hill, and colleagues identified potential predictors of decisional regret in a population-based cohort of 348 African-American men and 446 Caucasian men at approximately three years after the diagnosis of prostate cancer.

The researchers found that 12 percent of the participants experienced treatment decisional regret

Factors associated with decisional regret included androgen deprivation therapy (odds ratio [OR], 2.1), recent urinary bother (OR, 3.4), satisfaction with understanding potential side effects of treatment (very unsatisfied: OR, 13.3; somewhat unsatisfied: OR, 5.0; neutral: OR, 3.8), and treatment effect on the spousal relationship (very affected: OR, 3.9; somewhat affected: OR, 3.1; neutral: OR, 2.4).

RELATED: Zoledronic Acid Ineffective in Preventing Bone Metastases in Prostate Cancer

Among African-American patients, younger men were more likely to experience regret than older men (OR, 3.0). Older African-American patients were less likely to experience regret than older Caucasian patients (OR, 0.2).

"To our knowledge, this is the first study with sufficient power to examine racial differences in prostate cancer treatment decisional regret," the authors write.

One author disclosed financial ties to Accuray.

Reference

  1. Morris, Bonny B., MSPH, BSN, RN, et al. "Treatment decisional regret among men with prostate cancer: Racial differences and influential factors in the North Carolina Health Access and Prostate Cancer Treatment Project (HCaP-NC)." Cancer. DOI: 10.1002/cncr.29309. March 3, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs